Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 7/20 | 0.57 |
| ▸ | NOS1 | P29475 | 6/20 | 0.57 |
| ▸ | NOS3 | P29474 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21590075 | 1.00 | NOS2 (0.57) | NOS2NOS1NOS3KMT2AMEN1 | |
| SCHEMBL10279979 | 0.89 | NOS2 (0.51) | NOS2NOS1NOS3KMT2AMEN1 | |
| SCHEMBL826661 | 0.87 | NOS2 (0.53) | NOS2NOS1NOS3KMT2AMEN1 | |
| SCHEMBL15242543 | 0.86 | CES2 (0.44) | NOS2NOS1NOS3KMT2AMEN1 | |
| SCHEMBL10187366 | 0.85 | NOS2 (0.54) | NOS2NOS1NOS3KMT2AMEN1 | |
| SCHEMBL21590077 | 0.82 | NOS3 (0.60) | NOS2NOS1NOS3KMT2AMEN1 | |
| SCHEMBL21590080 | 0.82 | NOS3 (0.60) | NOS2NOS1NOS3KMT2AMEN1 | |
| SCHEMBL31669034 | 0.82 | NOS2 (0.47) | NOS2NOS1NOS3KMT2AMEN1 | |
| SCHEMBL21250709 | 0.80 | NOS2 (0.47) | NOS2NOS1NOS3KMT2AMEN1 | |
| SCHEMBL12028657 | 0.79 | NOS2 (0.53) | NOS2NOS1NOS3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378584-B2 | Methionine analogue synthesis | ENGENES BIOTECH GMBH (AT) | 2025-08-05 | — | — | US | claimed |
| EP-3807415-A1 | METHIONINE ANALOGUE SYNTHESIS | Engenes Biotech GmbH (AT) | 2021-04-21 | — | — | EP | claimed |
| WO-2019238725-A1 | METHIONINE ANALOGUE SYNTHESIS | ACIB GMBH - AUSTRIAN CENTRE OF INDUSTRIAL BIOTECHNOLOGY (AT) | 2019-12-19 | — | — | WO | claimed |
| US-12378584-B2 | Methionine analogue synthesis | ENGENES BIOTECH GMBH (AT) | 2025-08-05 | — | — | US | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | AMBRX, INC. | 2023-07-20 | — | — | US | disclosed |
| EP-3225248-B1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20130030160-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2012166560-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012166559-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012024452-A2 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20110294161-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2011087810-A1 | MODIFIED PORCINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011079293-A1 | TUMOR NECROSIS FACTOR-RELATED APOPTOSIS INDUCING LIGAND POLYPEPTIDES AND THEIR USES | AMBRX, INC (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010006214-A1 | FGF-21 NEUTRALIZING ANTIBODIES AND THEIR USES | AMBRX, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2006069220-A9 | MODIFIED HUMAN GROWTH HORMONE | AMBRX INC (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | IL2, IL2RA, TAP2 | NOS2 1049/4885NOS1 4161/4885NOS3 3388/4885 |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | NOS2 1667/4885NOS1 2210/4885NOS3 2480/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | NOS2 4241/4885NOS1 4297/4885NOS3 3906/4885 |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | CSF3R, GMFG, HDGF | NOS2 2298/4885NOS1 3226/4885NOS3 2522/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | NOS2 2216/4885NOS1 2705/4885NOS3 2785/4885 |
| US-20130030160-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | NOS2 21/4885NOS1 40/4885NOS3 25/4885 |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | RXFP1, RXFP2, RXFP3 | NOS2 396/4885NOS1 624/4885NOS3 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.